CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
DefenCath's Triumph | CorMedix's flagship product DefenCath shows strong market traction, driving a 131% stock return over the past year and outperforming broader market indices |
Strategic Partnerships | Explore CorMedix's commercial agreements with dialysis providers, including potential negotiations with a top U.S. dialysis provider, signaling market validation |
Financial Trajectory | Delve into CorMedix's financial performance, with Q3 revenues of $5 million and analyst price targets ranging from $11 to $19 per share |
Expansion Horizons | Learn about CorMedix's plans to expand DefenCath beyond hemodialysis, targeting total parenteral nutrition and pediatric hemodialysis markets for future growth |
Metrics to compare | CRMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRMDPeersSector | |
---|---|---|---|---|
P/E Ratio | 20.0x | −2.9x | −0.6x | |
PEG Ratio | 0.11 | 0.21 | 0.00 | |
Price/Book | 4.6x | 2.5x | 2.6x | |
Price / LTM Sales | 8.4x | 1.8x | 3.3x | |
Upside (Analyst Target) | 46.1% | 110.8% | 37.4% | |
Fair Value Upside | Unlock | 17.6% | 4.5% | Unlock |